Free Trial

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences logo
$60.37 -0.38 (-0.63%)
(As of 12/17/2024 ET)

Exact Sciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
17

Based on 18 Wall Street analysts who have issued ratings for Exact Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 1 has given a hold rating, and 17 have given a buy rating for EXAS.

Consensus Price Target

$72.94
20.82% Upside
According to the 18 analysts' twelve-month price targets for Exact Sciences, the average price target is $72.94. The highest price target for EXAS is $90.00, while the lowest price target for EXAS is $60.00. The average price target represents a forecasted upside of 20.82% from the current price of $60.37.
Get the Latest News and Ratings for EXAS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Exact Sciences and its competitors.

Sign Up

EXAS Analyst Ratings Over Time

TypeCurrent Forecast
12/19/23 to 12/18/24
1 Month Ago
11/19/23 to 11/18/24
3 Months Ago
9/20/23 to 9/19/24
1 Year Ago
12/19/22 to 12/19/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
18 Buy rating(s)
15 Buy rating(s)
14 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$72.94$74.47$78.14$96.11
Forecasted Upside20.82% Upside50.32% Upside10.32% Upside38.43% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Moderate Buy

EXAS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EXAS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Exact Sciences Stock vs. The Competition

TypeExact SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.94
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside20.82% Upside28,526.50% Upside12.04% Upside
News Sentiment Rating
Positive News

See Recent EXAS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/13/2024Bank of America
3 of 5 stars
 Lower TargetBuy ➝ Buy$75.00 ➝ $72.00+18.25%
11/26/2024TD Cowen
5 of 5 stars
 Boost TargetBuy ➝ Buy$82.00 ➝ $86.00+45.05%
11/26/2024BTIG Research
2 of 5 stars
 Boost TargetBuy ➝ Buy$65.00 ➝ $75.00+25.94%
11/21/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
11/11/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$85.00 ➝ $75.00+45.69%
11/6/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$84.00 ➝ $85.00+56.14%
11/6/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$80.00 ➝ $75.00+37.77%
11/6/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$95.00 ➝ $75.00+39.61%
11/6/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$82.00 ➝ $67.00+24.72%
11/6/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
V. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$80.00 ➝ $60.00+15.65%
11/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$75.00 ➝ $65.00+25.29%
11/6/2024Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Jackson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$67.00 ➝ $65.00-9.10%
11/6/2024Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$82.00 ➝ $65.00-9.10%
11/6/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$70.00 ➝ $67.00-6.31%
10/30/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$75.00 ➝ $90.00+26.26%
9/26/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform
8/27/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Couillard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$75.00+25.23%
6/27/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Nam
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$70.00+58.51%
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$90.00+32.92%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$95.00+44.99%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$75.00 ➝ $90.00-6.68%
5/5/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$73.00+10.96%
2/22/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$56.00 ➝ $76.00+24.06%
1/12/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$70.00 ➝ $75.00+9.59%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:01 AM ET.


EXAS Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Exact Sciences is $72.94, with a high forecast of $90.00 and a low forecast of $60.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There is currently 1 hold rating and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAS shares.

According to analysts, Exact Sciences's stock has a predicted upside of 20.82% based on their 12-month stock forecasts.

Analysts like Exact Sciences more than other "medical" companies. The consensus rating score for Exact Sciences is 2.94 while the average consensus rating score for "medical" companies is 2.81. Learn more on how EXAS compares to other companies.


This page (NASDAQ:EXAS) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners